Flexible, Modern Facilities
Our state-of-the-art facilities include 25 R&D labs, as well as a cGMP manufacturing plant with both single-use and stainless steel systems for upstream and downstream process development, formulation and fill-finish of microbial and mammalian cell culture-based products. Our flexible, integrated infrastructure enables us to develop, formulate and manufacture clients’ proteins and antibodies as well as the corresponding aseptic drug products at a range of scales.
We are continuously investing in the expansion of our facilities to better serve our global clients. To that end, we are increasing our microbial cGMP manufacturing capacity by adding a new production facility with 30-300-3,000 L working volume bioreactor train.